Source-grounded facts extracted from GALECTIN THERAPEUTICS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
GALECTIN THERAPEUTICS INC reported financial results for the year ended December 31, 2025.
“Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2025.”
Pol Boudes resigned as Chief Medical Officer at GALECTIN THERAPEUTICS INC.
“Dr. Jamil succeeds Dr. Pol Boudes as Chief Medical Officer of the Company, who resigned on July 26, 2024. Dr. Boudes’s last day of employment with the Company is August 1, 2024.”
Khurram Jamil changed role as Chief Medical Officer at GALECTIN THERAPEUTICS INC.
“On August 1, 2024, Galectin Therapeutics Inc. (the “Company”) announced the promotion of Dr. Khurram Jamil to Chief Medical Officer effective immediately.”
GALECTIN THERAPEUTICS INC reported the quarter ended March 31, 2024 results: net income net loss of $11.5 million, EPS ($0.19) per share.
“For the quarter ended quarter ended March 31, 2024, the Company reported a net loss applicable to common stockholders of $11.5 million, or ($0.19) per share, compared to a net loss applicable to common stockholders of $11.5 million, or ($0.19) per share for the quarter ended March 31, 2023.”
GALECTIN THERAPEUTICS INC reported the year ended December 31, 2023 results: net income net loss applicable to common stockholders of $44.8 million, or ($0.74) per share, EPS $(0.74).
“For the year ended December 31, 2023, the Company reported a net loss applicable to common stockholders of $44.8 million, or ($0.74) per share, compared to a net loss applicable to common stockholders of $38.9 million, or ($0.65) per share for the year ended December 31, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.